阻塞性冠心病功能完全血运重建后指南导向药物治疗的预后影响
本研究基于FAVOR III China试验中达到功能完全血运重建的3221例患者,评估指南导向药物治疗(GDMT)依从性对3年临床结局的影响。结果显示GDMT组从第2年起主要不良心脑血管事件(MACCE)显著低于非GDMT组,并持续至第3年。
要点
- 功能完全血运重建后,GDMT依从性仍显著影响远期预后。
- GDMT获益从第2年开始显现,持续至3年。
- 3年时仅35.3%患者仍坚持GDMT,依从性逐年下降。
核心结论
- 在达到功能完全血运重建的患者中,良好依从GDMT的获益从第2年开始显著,并持续至3年。
研究设计与样本
- 研究人群来自FAVOR III China试验中达到功能完全血运重建的患者,功能完全血运重建定义为基于定量血流分数(QFR)的残余功能SYNTAX评分为0,且仅在QFR≤0.80的血管中测量。
- GDMT定义为根据当代指南推荐联合使用单联或双联抗血小板治疗、β受体阻滞剂和他汀,联合或不联合ACE抑制剂或血管紧张素受体拮抗剂;患者分为GDMT组(4类药物全部依从)和非GDMT组(依从0-3类药物)。
- 共3221例(85.2%)患者达到功能完全血运重建。
主要发现
- 在1个月、6个月、1年、2年和3年时,分别有1964例(61.2%)、1919例(59.9%)、1545例(48.4%)、1483例(46.6%)和1084例(35.3%)患者坚持GDMT。
- 3年内共313例(10.2%)患者发生MACCE。
- GDMT组与非GDMT组在 first year 内MACCE发生率相似,但从第2年起GDMT组显著低于非GDMT组(校正HR:0.66,95%CI:0.51至0.85;p<0.01),并持续至第3年(校正HR:0.65,95%CI:0.50至0.85;p<0.01)。
关键数值与推荐
- 功能完全血运重建定义:基于QFR的残余功能SYNTAX评分为0,仅在QFR≤0.80的血管中测量。
- GDMT定义:联合使用单联或双联抗血小板治疗、β受体阻滞剂和他汀,联合或不联合ACE抑制剂或血管紧张素受体拮抗剂。
- 主要终点:3年主要不良心脑血管事件(MACCE),包括死亡、心肌梗死、卒中和缺血驱动的血运重建。
临床怎么用
- 对于达到功能完全血运重建的阻塞性冠心病患者,应强调长期坚持GDMT以改善远期预后。
- GDMT的获益从第2年开始显现,临床随访中需关注患者长期用药依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Functional complete revascularisation (FCR) has been proven to be associated with superior prognosis following percutaneous coronary intervention. Whether guideline-directed medical therapy (GDMT) still impacts clinical outcomes in patients who have achieved FCR requires further evaluation. METHODS: The study population was drawn from patients who achieved FCR in the FAVOR III China trial, defined as a quantitative flow ratio (QFR)-based residual functional Synergy between percutaneous coronary intervention with taxus and cardiac Surgery score of 0, measured only in vessels with QFR≤0.80. GDMT was defined as the combination of single or dual antiplatelet therapy, a beta-blocker and a statin, with or without an ACE inhibitor or angiotensin receptor blocker, according to contemporary guideline recommendations. Patients were categorised into the GDMT group (compliance with all 4 agents) or non-GDMT group (compliance with 0-3 agents). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) at 3 years, a composite of death, myocardial infarction, stroke and ischaemia-driven revascularisation. RESULTS: Among 3221 (85.2%) patients who achieved FCR, a total of 1964 (61.2%), 1919 (59.9%), 1545 (48.4%), 1483 (46.6%) and 1084 (35.3%) patients adhered to GDMT at 1 month, 6 months, 1 year, 2 years and 3 years, respectively. The MACCE occurred in 313 (10.2%) patients through 3 years. The rate of MACCE was similar between GDMT and non-GDMT groups within the first year, but significantly lower in the GDMT group from the second year (adjusted HR: 0.66, 95% CI: 0.51 to 0.85; p<0.01) and sustained until the third year (adjusted HR: 0.65, 95% CI: 0.50 to 0.85; p<0.01), compared with the non-GDMT group. CONCLUSIONS: In patients who achieved FCR, the benefit of good adherence to GDMT remained significant, starting from the second year and continuing up to 3 years. TRIAL REGISTRATION NUMBER: NCT03656848.
引用
- Geng Y, Guan C, Jiang Y, et al. Prognostic impact of guideline-directed medical therapy after functionally complete revascularisation in patients with obstructive coronary artery diseases. Heart. 2026. PMID: 40780826. doi:10.1136/heartjnl-2025-325670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。